Can Peregrine Match Celgene? No.

Celgene (NASDAQ: CELG  ) made major headlines in January after releasing impressive phase 3 data for its cancer drug Abraxane in advanced pancreatic cancer. Today, it looked like Peregrine Pharmaceuticals (NASDAQ: PPHM  ) had some impressive data of its own. Shares of the stock were surging higher as soon as a press release announcing phase 2 results for bavituximab in late-stage pancreatic cancer hit the wire.

Then investors actually looked at the results, and reality set in. Follow along in the video below as health care bureau chief Brenton Flynn discusses why today's investor optimism was so short-lived.

Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today -- along with a free year of updates -- simply click here now.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 14, 2013, at 9:43 AM, azurlo wrote:

    Your statement that investing in biotechs is similar to betting money in a casino holds certainly true for those unable to read into the complexity of clinical trial data.

    For instance, you need to know how to intepreter an actuarial KM comparison. Difference at the median point is not the whole story, particularly with biological agents.

    So I am surprised that you focused your analysis only on the median OS, disregarding the HR. At .75 this clearly points to good survival in a subgroup of patients, confirming the signal observed with RR. Thus the claims of PPHM management may not be just biased hype. They probably cannot tell more at this stage, as otherwise the trial results will not be accepted at any major conference such as ASCO.

    The sell off after all may provide a great opportunity, at least for those who do not fancy a trip to Las Vegas.

Add your comment.

DocumentId: 2253334, ~/Articles/ArticleHandler.aspx, 7/23/2014 2:29:48 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement